[go: up one dir, main page]

WO2008078109A3 - Medicament - Google Patents

Medicament Download PDF

Info

Publication number
WO2008078109A3
WO2008078109A3 PCT/GB2007/005010 GB2007005010W WO2008078109A3 WO 2008078109 A3 WO2008078109 A3 WO 2008078109A3 GB 2007005010 W GB2007005010 W GB 2007005010W WO 2008078109 A3 WO2008078109 A3 WO 2008078109A3
Authority
WO
WIPO (PCT)
Prior art keywords
agelastatin
medicament
metastasis
modulators
analogue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/GB2007/005010
Other languages
French (fr)
Other versions
WO2008078109A2 (en
Inventor
Mohamed K. El-Tanani
Karl J. Hale
Soraya Manaviazar
Patrick G. Johnston
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Queens University of Belfast
Original Assignee
Queens University of Belfast
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Queens University of Belfast filed Critical Queens University of Belfast
Publication of WO2008078109A2 publication Critical patent/WO2008078109A2/en
Anticipated expiration legal-status Critical
Publication of WO2008078109A3 publication Critical patent/WO2008078109A3/en
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

There is disclosed the use of (-)-Agelastatin and / or an agelastatin analogue in the treatment of metastatic disease, pharmaceutical compositions comprising Agelastatin and other active agents, for example chemotherapeutic agents and an assay for the identification of modulators of metastasis and / or invasive cancer.
PCT/GB2007/005010 2006-12-22 2007-12-24 Medicament Ceased WO2008078109A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0625783.6A GB0625783D0 (en) 2006-12-22 2006-12-22 Medicament
GB0625783.6 2006-12-22

Publications (2)

Publication Number Publication Date
WO2008078109A2 WO2008078109A2 (en) 2008-07-03
WO2008078109A3 true WO2008078109A3 (en) 2009-09-11

Family

ID=37758951

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2007/005010 Ceased WO2008078109A2 (en) 2006-12-22 2007-12-24 Medicament

Country Status (2)

Country Link
GB (1) GB0625783D0 (en)
WO (1) WO2008078109A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962383B2 (en) 2013-09-19 2018-05-08 Massachusetts Institute Of Technology Compounds, compositions and methods of agelastatin alkaloids

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9353150B2 (en) 2012-12-04 2016-05-31 Massachusetts Institute Of Technology Substituted pyrazino[1′,2′:1 ,5]pyrrolo[2,3-b]-indole-1,4-diones for cancer treatment
WO2017197045A1 (en) 2016-05-11 2017-11-16 Movassaghi Mohammad Convergent and enantioselective total synthesis of communesin analogs
US11932650B2 (en) 2017-05-11 2024-03-19 Massachusetts Institute Of Technology Potent agelastatin derivatives as modulators for cancer invasion and metastasis
US10640508B2 (en) 2017-10-13 2020-05-05 Massachusetts Institute Of Technology Diazene directed modular synthesis of compounds with quaternary carbon centers
WO2020247054A1 (en) 2019-06-05 2020-12-10 Massachusetts Institute Of Technology Compounds, conjugates, and compositions of epipolythiodiketopiperazines and polythiodiketopiperazines and uses thereof
WO2022182415A1 (en) 2021-02-24 2022-09-01 Massachusetts Institute Of Technology Himastatin derivatives, and processes of preparation thereof, and uses thereof
US20240254134A1 (en) * 2021-05-11 2024-08-01 Baylor University Agelastatin a derivatives and related methods

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106343A2 (en) * 2003-05-30 2004-12-09 Ufc Limited Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids
WO2006055578A2 (en) * 2004-11-16 2006-05-26 Temple University - Of The Commonwealth Systems Of Higher Education Asymmetric synthesis of (-)-agelastatin a

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004106343A2 (en) * 2003-05-30 2004-12-09 Ufc Limited Agelastatin derivatives of antitumour and gsk-3beta-inhibiting alkaloids
WO2006055578A2 (en) * 2004-11-16 2006-05-26 Temple University - Of The Commonwealth Systems Of Higher Education Asymmetric synthesis of (-)-agelastatin a

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FURGER K A ET AL: "THE FUNCTIONAL AND CLINICAL ROLES OF OSTEOPONTIN IN CANCER AND METASTASIS", CURRENT MOLECULAR MEDICINE, BENTHAM SCIENCE PUBLISHERS, vol. 1, no. 5, 1 January 2001 (2001-01-01), pages 621 - 632, XP008055151, ISSN: 1566-5240 *
HALE KARL J ET AL: "Chemical biology and mechanism of action studies on the antitumour agent, (-)-Agelastatin A.", ABSTRACTS OF PAPERS AMERICAN CHEMICAL SOCIETY, vol. 228, no. Part 1, August 2004 (2004-08-01), & MEETING OF THE DIVISION OF CHEMICAL TOXICOLOGY OF THE AMERICAN-CHEMICAL-SOCIETY HELD AT THE 228TH N; PHILADELPHIA, PA, USA; AUGUST 22 -26, 2004, pages U909, XP009112708, ISSN: 0065-7727 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9962383B2 (en) 2013-09-19 2018-05-08 Massachusetts Institute Of Technology Compounds, compositions and methods of agelastatin alkaloids

Also Published As

Publication number Publication date
GB0625783D0 (en) 2007-02-07
WO2008078109A2 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
WO2008078109A3 (en) Medicament
WO2008028965A3 (en) Inhibitors of protein phosphatase 1, gadd34 and protein phosphatase 1/gadd34 complex, preparation and uses thereof
WO2007146426A3 (en) Nanoshells for drug delivery
WO2008017867A3 (en) Antiretroviral solid oral composition with at least one water insoluble polymer
IL228952A0 (en) Medicinal preparations containing ferric-citrate for reducing the level of phosphate in the serum, and their use in the preparation of medicines for the treatment or relief of calcium-related disorders
WO2007076423A3 (en) INHIBITORS OF Akt ACTIVITY
WO2009049184A9 (en) Systemic administration of chlorotoxin agents for the diagnosis and treatment of tumors
WO2008141308A3 (en) Gene expression and pain
WO2004041269A3 (en) New use for pharmaceutical composition
ECSP077238A (en) COMPOSITIONS FOR DELIVERY OF HIGHLY SOLUBLE DRUGS IN WATER
WO2006013441A3 (en) Use of probiotic bacteria for the preparation of topical compositions for skin protection
EP1859793A4 (en) Novel combinational use of sulfonamide compound
WO2006015263A3 (en) Lonidamine analogs
WO2008076954A3 (en) Heterocycle compounds and methods of use thereof
WO2009106819A3 (en) Biological materials and uses thereof
WO2007064945A3 (en) Cancer therapies and pharmaceutical compositions used therein
BRPI0513455A (en) flavor masking formulation comprising the drug in a delayed dissolution form and / or cyclodextrin in an improved dissolution form
BRPI0717369A2 (en) COMPOUND, MEDICINAL PRODUCT, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
EP4527855A3 (en) Stable igg4 based binding agent formulations
CL2007002619A1 (en) COMPOUNDS DERIVED FROM 3-AZA-BICICLO [4.1.0] HEPTANO; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DEPRESSION.
WO2008054808A3 (en) Elvucitabine pharmaceutical compositions
WO2007061939A3 (en) Metabolite derivatives of the hdac inhibitor fk228
IL195935A0 (en) 18-methyl-19-nor-androst-4-en 17,17-spiroether (18-methyl-19-nor-20-spirox-4-en-3-one) and pharmaceutical preparations containing the same
WO2005118601A3 (en) Sulfonylethyl phosphorodiamidates for use in the treatment of cancer
WO2006133707A3 (en) Anti-cancer combination treatment and kit-of-part

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07858809

Country of ref document: EP

Kind code of ref document: A2

122 Ep: pct application non-entry in european phase

Ref document number: 07858809

Country of ref document: EP

Kind code of ref document: A2